The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes

被引:10
|
作者
Shehata, Mohamed A. [1 ]
Elhaddad, Ahmed [1 ]
El-Attar, Ashraf A. [1 ]
Shehata, Sherif M. [1 ]
机构
[1] Tanta Univ, Fac Med, Dept Gen Surg, Pediat Surg Unit, El Geish St, Tanta 31257, Egypt
关键词
Laparoscopic sleeve gastrectomy; Antral resection; Antral preservation; Obesity; Adolescent; GLP-1; C-peptide; Glycemic control; Diabetes; T2D; BARIATRIC SURGERY; CHILDREN; SECRETION; IMPACT; PHYSIOLOGY; RESECTION; RISK; LSG;
D O I
10.1007/s11695-021-05590-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose The aim of this study was to compare the effect of antral resection versus antral preservation sleeve gastrectomy on the post-operative GLP-1, glycemic control, and weight loss in adolescents suffering from severe obesity and type 2 diabetes (T2D). Materials and methods This study included 36 adolescents. Patients were randomly divided into 2 groups: group (A) and group (B). Each group included 18 patients who underwent LSG, starting transection at 2 cm or 5 cm from the pyloric ring in group(A) and group (B), respectively. They were followed up at 1, 3, 6, 12, and 24 months post-operatively. The outcomes were the post-operative GLP-1 response, glycemic control, weight loss, and safety. Results The improvements in the body mass index and the percentage of excess weight loss (%EWL) were statistically significant within each group. The mean GLP-1 levels showed significant increase at the 1, 3, and 6 months but not in the 12 and 24 months in all the studied samples within each group. The mean HbA1c levels and post-prandial serum C-peptide significantly improved within each group (P < 0.05). No statistical differences in the weight loss, %EWL, GLP-1, HbA1c, C-peptide changes, and complication rates were observed between both groups. Diabetic remission was significantly higher (88.9%) in group (A). Conclusions LSG resulted in generalized significant GLP-1 initial response that decreased over time. The reduced antrum size did not influence the GLP-1 response, glycemic control, or insulin resistance, but resulted in significantly better T2D remission. Since the study examines a small number of patients, further studies are needed.
引用
收藏
页码:4376 / 4385
页数:10
相关论文
共 50 条
  • [1] The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes
    Mohamed A. Shehata
    Ahmed Elhaddad
    Ashraf A. El-Attar
    Sherif M. Shehata
    Obesity Surgery, 2021, 31 : 4376 - 4385
  • [2] Glucagon-like peptide-1 (GLP-1) levels in obese patients with and without type 2 diabetes.
    Mannucci, E
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Ciani, S
    Messeri, G
    Rotella, CM
    DIABETOLOGIA, 2000, 43 : A146 - A146
  • [3] Preserved Inhibitory Effect of Glucagon-Like Peptide-1 (GLP-1) on Glucagon Secretion in Type 2 Diabetes Mellitus
    Hare, Kristine J.
    Knop, Filip K.
    Asmar, Meena
    Larsen, Steen
    Madsbad, Sten
    Holst, Jens J.
    Vilsboll, Tina
    DIABETES, 2009, 58 : A372 - A372
  • [4] Glucagon-like peptide-1 (GLP-1) in obese subjects with and without type 2 diabetes
    Rotella, CM
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Messeri, G
    Mannucci, E
    DIABETES, 2000, 49 : A1 - A1
  • [6] Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
    Yuya Fujishima
    Norikazu Maeda
    Kana Inoue
    Susumu Kashine
    Hitoshi Nishizawa
    Ayumu Hirata
    Junji Kozawa
    Tetsuyuki Yasuda
    Kohei Okita
    Akihisa Imagawa
    Tohru Funahashi
    Iichiro Shimomura
    Cardiovascular Diabetology, 11
  • [7] Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
    Fujishima, Yuya
    Maeda, Norikazu
    Inoue, Kana
    Kashine, Susumu
    Nishizawa, Hitoshi
    Hirata, Ayumu
    Kozawa, Junji
    Yasuda, Tetsuyuki
    Okita, Kohei
    Imagawa, Akihisa
    Funahashi, Tohru
    Shimomura, Iichiro
    CARDIOVASCULAR DIABETOLOGY, 2012, 11
  • [8] The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
    Yin, Jun
    Liu, Yuexing
    Jia, Weiping
    CHINESE SCIENCE BULLETIN-CHINESE, 2024, 69 (35): : 5094 - 5099
  • [9] Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates
    Abdelmannan, Dima
    AlBuflasa, Manal
    Ajlouni, Heitham
    Zidan, Marwan
    Rahman, Farya
    Farooqi, Muhammad Hamed
    Caballero, A. Enrique
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 207
  • [10] Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): The role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress
    Bojanowska, E
    MEDICAL SCIENCE MONITOR, 2005, 11 (08): : RA271 - RA278